According to the Zhitong Finance App, Jiashitang (002462.SZ) disclosed its 2022 annual report. The company achieved annual revenue of 26.220 billion yuan, an increase of 2.32% over the previous year. Net profit attributable to shareholders of listed companies was 297 million yuan, a year-on-year decrease of 16.09%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 284 million yuan, a year-on-year decrease of 17.91%. Basic earnings per share were $1.02 per share. It is proposed to distribute a cash dividend of 3.1 yuan (tax included) for every 10 shares.

Up to now, the company's pharmaceutical and device sales business covers more than 4,000 mainstream medical institutions. The professional coverage of terminal hospitals and doctors forms a complete business chain, derives a high level of value from traffic and data, and also lays the foundation for developing rehabilitation medical services.